Update on HIV-1 diversity in Africa: A decade in review

AIDS Reviews

Volumn 14, Issue 2, 2012, Pages 83-100

  Lihana, Raphael W ^a   Ssemwanga, Deogratius ^b   Abimiku, Alash'le ^c,d   Ndembi, Nicaise ^c  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

Author keywords

Africa; Genetic diversity; HIV 1; Subtypes

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

AFRICA; BIODIVERSITY; CD8+ T LYMPHOCYTE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NONHUMAN; PHYLOGENY; PREVALENCE; REVIEW; VIRUS CLASSIFICATION; VIRUS LOAD; VIRUS STRAIN;

AFRICA; AIDS VACCINES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PHYLOGENY; POPULATION SURVEILLANCE; RECOMBINATION, GENETIC;

EID: 84862562395     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (273)

1. UNAIDS. (2010). Report on the global AIDS epidemic 2010.
2. Robertson D, Anderson J, Bradac J, et al. HIV-1 nomenclature proposal. Science. 2000;288:55-6.
3. Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS. 2003;17:2547-60.
4. Hemelaar J, Gouws E, Ghys P, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25:679-89.
5. Salemi M. Toward a robust monitoring of HIV subtypes distribution worldwide. AIDS. 2011;25:713-14.
6. Vallari A, Holzmayer V, Harris B, et al. (2011). Confirmation of putative HIV-1 group P in Cameroon. J Virol. 2011;85:1403-7.
7. Arien K, Abraha A, Quiñones-Mateu M, Kestens L, Vanham G, Arts EJ. (2005). The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol. 2005;79:8979-90.
8. Troyer R, McNevin J, Liu Y, et al. (2009). Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5:e1000365.
9. Hue S, Clewley J, Cane P, Pillay D. HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS. 2004;18:719-28.
10. Walter B, Armitage A, Graham S, et al. Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility. AIDS. 2009;23:1047-57.
11. Conroy S, Laeyendecker O, Redd A, et al. (2010). Changes in the distribution of HIV type 1 subtypes D and A in Rakai District, Uganda between 1994 and 2002." AIDS Res Hum Retroviruses. 2010;26:1087-91.
12. Kuiken C, Thakallapalli R, Esklid A, de Ronde A. Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus. Am J Epidemiol. 2000;152:814-22.
13. Papathanasopoulos M, Hunt G, Tiemessen C. Evolution and diversity of HIV-1 in Africa - a review. Virus Genes. 2003;26:151-63.
14. Kilmarx P. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4:240-6.
15. Woodman Z, Williamson C. HIV molecular epidemiology: transmission and adaptation to human populations. Curr Opin HIV AIDS. 2009;4:247-52.
16. Carr J, Wolfe N, Torimiro J, et al. HIV-1 recombinants with multiple parental strains in low-prevalence, remote regions of Cameroon: evolutionary relics? Retrovirology. 2010;7:39.
17. Carr J. Viral diversity as a challenge to HIV-1 vaccine development. Curr Opin HIV AIDS. 2006;1:294-300.
18. Taylor B, Sobieszczyk M, McCutchan F, Hammer S. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;358:1590-602.
19. Lemey P, Pybus O, Rambaut A, et al. The molecular population genetics of HIV-1 group O. Genetics. 2004;167:1059-68.
20. Keele B, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science. 2006;313:523-6.
21. Van Heuverswyn F, Li Y, Bailes E, et al. Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology. 2007;368:155-71.
22. Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med. 2009 Aug;15(8):871-2.
23. Van Heuverswyn F, Li Y, Neel C, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature. 2006;444:164.
24. Takehisa J, Kraus M, Ayouba A, et al. (2009). Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol. 2009;83:1635-48.
25. Lemey P, Pybus O, Wang B, et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci USA. 2003;100:6588-92.
26. Damond F, Worobey M, Campa P, et al. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification." AIDS Res Hum Retroviruses. 2004;20:666-72.
27. Peeters M. Cross-species transmissions of simian retroviruses in Africa and risk for human health. Lancet. 2004;363:911-12.
28. Yamaguchi J, Vallari A, Ndembi N, et al. HIV type 2 intergroup recombinant identified in Cameroon. AIDS Res Hum Retroviruses. 2008;24:86-91.
29. Ibe S, Yokomaku Y, Shiino T, et al. HIV-2 CRF01-AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr. 2010;54:241-7.
30. Rambaut A, Robertson D, Pybus O, et al. Human immunodeficiency virus. Phylogeny and the origin of HIV-1. Nature. 2001;410:1047-8.
31. Worobey M, Gemmel M, Teuwen D, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature. 2008;455:661-4.
32. Worobey M, Telfer P, Souquière S, et al. Island biogeography reveals the deep history of SIV. Science. 2010;329:1487.
33. Faria N, Suchard M, Abecasis A, et al. Phylodynamics of the HIV-1 CRF02-AG clade in Cameroon. Infect Genet Evol. 2011. [Epub ahead of print].
34. Veras N, Santoro M, Gray R, et al. Molecular epidemiology of HIV Type1 CRF02-AG in Cameroon and African patients living in Italy. AIDS Res Hum Retroviruses. 2011;27:1173-82.
35. HIV Sequence Database. http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/ CRFs.html [accessed February 2012].
36. Bodelle P, Vallari A, Coffey R, et al. Identification and genomic sequence of an HIV type 1 group N isolate from Cameroon. AIDS Res Hum Retroviruses. 2004;20:902-8.
37. Yamaguchi J, Coffey R, Vallari A, et al. Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. AIDS Res Hum Retroviruses. 2006;22:83-92.
38. Yamaguchi J, McArthur C, Vallari A, et al. HIV-1 Group N: evidence of ongoing transmission in Cameroon. AIDS Res Hum Retroviruses. 2006;22:453-7.
39. Vallari A, Bodelle P, Ngansop C, et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses. 2010;26:109-15.
40. Aghokeng A, Mpoudi-Ngole E, Dimodi H, et al. Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS One. 2009;4:e7702.
41. Plantier J, Djemai M, Lemee V, et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol. 2009;47:2906-11.
42. Depatureaux A, Charpentier C, Leoz M, et al. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr. 2011;56:139-45.
43. Ndembi N, Iwamoto S, Ngansop C, et al. High frequency of HIV-1 dual infections in Cameroon, West Central Africa. J Acquir Immune Defic Syndr. 2011;57:e25-7.
44. Sire J, Vray M, Merzouk M, et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr. 2011;56:239-43.
45. Kaleebu P, Nankya I, Yirrell D, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr. 2007;45:28-33.
46. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr. 2010;54:180-4.
47. Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.
48. Chan P, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther. 2009;3:447-65.
49. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182-5.
50. Brenner B, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9-13.
51. Dobard C, Johnson J, Garcia-Lerma J, Heneine W. Recombinant viruses expressing subtype B or subtype C reverse transcriptase reveal no difference in therate of K65R resistance to tenofovir in cell culture. XVIII International HIV Drug ResistanceWorkshop, Mort Myers, FL, 2009.
52. Grossman Z, Istomin V, Averbuch D, et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS. 2004;18:909-15.
53. Lemey P, Rambaut A, Pybus O. HIV evolutionary dynamics within and among hosts. AIDS Rev. 2006;8:125-40.
54. Lemey P, Lott M, Martin D, Moulton V. Identifying recombinants in human and primate immunodeficiency virus sequence alignments using quartet scanning. BMC Bioinformatics. 2009;27:126.
55. Abecasis A, Vandamme A, Lemey P. Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol. 2009;83:12917-24.
56. Letourneau S, Im E, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One. 2007;2:e984.
57. Kaleebu P, Abimiku A, El Halabi S, et al. African AIDS vaccine programme for a coordinated and collaborative vaccine development effort on the continent. PLoS Med. 2008;5:e236.
58. Serwanga J, Mugaba S, Pimego E, et al. Profile of T-cell recognition of HIV-1 consensus group M Gag and Nef peptides in a clade A1 and D infected Ugandan population. AIDS Res Hum Retroviruses. 2011. [Epub ahead of print].
59. Rambaut A, Posada D, Crandall K, Holmes E. The causes and consequences of HIV evolution. Nat Rev Genet. 2004;5:52-61.
60. Abecasis A, Paraskevis D, Epalanga M, et al. HIV-1 genetic variants circulation in the North of Angola. Infect Genet Evol. 2005;5:231-7.
61. Bartolo I, Epalanga M, Bartolomeu J, et al. High genetic diversity of human immunodeficiency virus type 1 in Angola. AIDS Res Hum Retroviruses. 2005;21:306-10.
62. Castelbranco EP, da Silva Souza E, Cavalcanti A, Martins A, de Alencar L, Tanuri A. Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola. AIDS Res Hum Retroviruses. 2010;26:1313-16.
63. Loemba H, Brenner B, Parniak M, et al. Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana. Antivir Ther. 2002;7:141-8.
64. Loemba H, Brenner B, Parniak M, et al. Polymorphisms of cytotoxic Tlymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res. 2002;56:129-42.
65. Doualla-Bell F, Gaseitsiwe S, Ndungú T, et al. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients." Antivir Chem Chemother. 2004;15:189-200.
66. Bussmann H, Novitsky V, Wester W, et al. HIV-1 subtype C drug-resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother. 2005;16:103-15.
67. Novitsky V, Wester C, DeGruttola V, et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007;23:868-78.
68. Petch L, Hoffman I, Jere C, et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from anti-retroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses. 2005;21:799-805.
69. Bredell H, Martin D, Van Harmelen J, et al. HIV type 1 subtype C gag and nef diversity in Southern Africa. AIDS Res Hum Retroviruses. 2007;23:477-81.
70. Kwiek J, Russell E, Dang J, et al. The molecular epidemiology of HIV-1 envelope diversity during HIV-1 subtype C vertical transmission in Malawian mother-infant pairs. AIDS. 2008;22:863-71.
71. Bansode V, Drebert Z, Travers S, et al. Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. AIDS Res Hum Retroviruses. 2011;27:439-44.
72. Bellocchi M, Forbici F, Palombi L, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol. 2005;76:452-8.
73. Lahuerta M, Aparicio E, Bardaji A, et al. Rapid spread and genetic diversification of HIV type 1 subtype C in a rural area of southern Mozambique. AIDS Res Hum Retroviruses. 2008;24:327-35.
74. Bartolo I, Casanovas J, Bastos R, et al. HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique. J Acquir Immune Defic Syndr. 2009;51:323-31.
75. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg. 2009;103:607-12.
76. Abreu C, Martins A, Arruda M, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch Virol. 2008;153:2013-17.
77. Scriba T, Treurnicht F, Zeier M, et al. Characterization and phylogenetic analysis of South African HIV-1 subtype C accessory genes. AIDS Res Hum Retroviruses. 2001;17:775-81.
78. Gordon M, De Oliveira T, Bishop K, et al. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies. J Virol. 2003;77:2587-99.
79. Hunt G, Papathanasopoulos M, Gray G, Tiemessen C. Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates. Virus Genes. 2003;26:49-56.
80. Walker P, Cilliers T, Choge I, Taylor N, Cohen S, Morris L. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006;78:1262-8.
81. Jacobs G, Laten A, van Rensburg E, et al. (2008). Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatmentnaive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses. 2008;24:1009-12.
82. Marconi V, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in Kwa-Zulu Natal, South Africa. Clin Infect Dis. 2008;46:1589-97.
83. Huang K, Goedhals D, Fryer H, et al. Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa. Antivir Ther. 2009;14:975-84.
84. Jacobs G, Loxton A, Laten A, et al. Emergence and diversity of different HIV-1 subtypes in South Africa, 2000-2001. J Med Virol. 2009;81:1852-9.
85. Romani B, Glashoff R, Engelbrecht S. Molecular and phylogenetic analysis of HIV type 1 vpr sequences of South African strains. AIDS Res Hum Retroviruses. 2009;25:357-62.
86. Wilkinson E, Engelbrecht S. Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa. Infect Genet Evol. 2009;9:840-6.
87. Fish M, Hewer R, Wallis C, et al. Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses. 2010;26:489-93.
88. Papathanasopoulos M, Vardas E, Wallis C, et al. Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study. AIDS Res Hum Retroviruses. 2010;26:705-9.
89. Li J, Lipscomb J, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011;203:798-802.
90. Price M, Wallis C, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011;27:5-12.
91. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses. 2003;19:151-60.
92. Li M, Salazar-Gonzalez J, Derdeyn C, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80:11776-90.
93. Haaland R, Hawkins P, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5:e1000274.
94. Gonzalez S, Gondwe C, Tully D, et al. Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in Zambia. AIDS Res Hum Retroviruses. 2010;26:795-803.
95. Hamers R, Siwale M, Wallis C, et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010;55:95-101.
96. Kantor R, Zijenah L, Shafer W, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2002;18:1407-13.
97. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20:1391-9.
98. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses. 2007;23:1055-61.
99. Bredell H, Williamson C, Sonnenberg P, Martin D, Morris L. Genetic characterization of HIV type 1 from migrant workers in three South African gold mines. AIDS Res Hum Retroviruses. 1998;14:677-84.
100. Bredell H, Hunt G, Casteling A, et al. HIV-1 Subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses. 2002;18:681-3.
101. Deho L, Walwema R, Cappelletti A, et al. Subtype assignment and phylogenetic analysis of HIV type 1 strains in patients from Swaziland. AIDS Res Hum Retroviruses. 2008;24:323-5.
102. Ndembi N, Takehisa J, Zekeng L, et al. Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr. 2004;37:1641-50.
103. Ndembi N, Lyagoba F, Nanteza B, et al. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses. 2008;24:889-95.
104. Hamers R, Oyomopito R, Kityo C, et al. Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance - HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2011. [Epub ahead of print].
105. Ndembi N, Hamers R, Sigaloff K, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS. 2011;25:905-10.
106. Gianella S, Delport W, Pacold M, et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol. 2011;85:8359-67.
107. Bartolo I, Rocha C, Bartolomeu J, et al. Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. Infect Genet Evol. 2009;9:672-82.
108. Guimaraes M, Vicente A, Otsuki K, et al. Close phylogenetic relationship between Angolan and Romanian HIV-1 subtype F1 isolates. Retrovirology. 2009;6:39.
109. Bello G, Guimaraes M, Morgado M. Evolutionary history of HIV-1 subtype B and F infections in Brazil. AIDS. 2006;20:763-8.
110. Bello G, Eyer-Silva W, Couto-Fernandez J, et al. Demographic history of HIV-1 subtypes B and F in Brazil. Infect Genet Evol. 2007;7:263-70.
111. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, Sugiura W. (2007). Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res Hum Retroviruses. 2007;23:564-8.
112. Abebe A, Pollakis G, Fontanet A, et al. Identification of a genetic subcluster of HIV type 1 subtype C (C') widespread in Ethiopia. AIDS Res Hum Retroviruses. 2000;16:1909-14.
113. Keys B, Karis J, Fadeel B, et al. V3 sequences of paired HIV-1 isolates from blood and cerebrospinal fluid cluster according to host and show variation related to the clinical stage of disease. Virology. 1993;196:475-83.
114. Louwagie J, McCutchan F, Peeters M, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 1993;7:769-80.
115. Louwagie J, Janssens W, Mascola J, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol. 1995;69:263-71.
116. Naghavi M, Salminen M, Sönnerborg A, Vahlne A. DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G. AIDS Res Hum Retroviruses. 1999;15:485-8.
117. Naghavi M, Schwartz S, Sönnerborg A, Vahlne A. Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1. AIDS Res Hum Retroviruses. 1999;15:1293-303.
118. Cornelissen M, van Den Burg R, Zorgdrager F, Goudsmit J. Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa. J Gen Virol. 2000;81:515-23.
119. Hierholzer M, Graham R, El Khidir I, et al. HIV type 1 strains from East and West Africa are intermixed in Sudan. AIDS Res Hum Retroviruses. 2002;18:1163-6.
120. Maslin J, Rogier C, Berger F, et al. Epidemiology and genetic characterization of HIV-1 isolates in the general population of Djibouti (Horn of Africa). J Acquir Immune Defic Syndr. 2005;39:129-32.
121. Hussein M, Abebe A, Pollakis G, et al. HIV-1 subtype C in commerical sex workers in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr. 2000;23:120-7.
122. Harris M, Maayan S, Kim B, et al. A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions. AIDS Res Hum Retroviruses. 2003;19:1125-33.
123. Pollakis G, Abebe A, Kliphuis A, et al. Recombination of HIV type 1C (C′/C″) in Ethiopia: possible link of EthHIV-1C′ to subtype C sequences from the high-prevalence epidemics in India and Southern Africa." AIDS Res Hum Retroviruses. 2003;19:999-1008.
124. Abegaz W, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther. 2008;13(Suppl 2):89-94.
125. Gray R, Tatem A, Lamers S, et al. Spatial phylodynamics of HIV-1 epidemic emergence in east Africa. AIDS. 2009;23:F9-17.
126. Dowling W, Kim B, Mason C, et al. Forty-one near full-length HIV-1 sequences from Kenya reveal an epidemic of subtype A and A-containing recombinants. AIDS. 2002;16:1809-20.
127. Land A, Luo M, Pilon R, et al. High prevalence of genetically similar HIV-1 recombinants among infected sex workers in Nairobi, Kenya. AIDS Res Hum Retroviruses. 2008;24:1455-60.
128. Hue S, Hassan A, Nabwera H, et al. HIV Type 1 in a rural coastal town in Kenya Shows multiple introductions with many subtypes and much recombination. AIDS Res Hum Retroviruses. 2011. [Epub ahead of print].
129. Yang C, Li M, Shi Y, et al. Genetic diversity and high proportion of intersubtype recombinants among HIV type 1-infected pregnant women in Kisumu, western Kenya. AIDS Res Hum Retroviruses. 2004;20:565-74.
130. Steain M, Wang B, Yang C, et al. HIV type 1 sequence diversity and dual infections in Kenya. AIDS Res Hum Retroviruses. 2005;21:882-5.
131. Arroyo M, Sateren W, Foglia G, et al. Short communication: HIV type 1 genetic diversity among tea plantation workers in Kericho, Kenya. AIDS Res Hum Retroviruses. 2009;25:1061-4.
132. Lihana R, Khamadi S, Lubano K, et al. Genetic characterization of HIV type 1 among patients with suspected immune reconstitution inflammatory syndrome after initiation of antiretroviral therapy in Kenya. AIDS Res Hum Retroviruses. 2010;26:833-8.
133. Kageha S, Lihana R, Okoth V, et al. HIV type 1 subtype surveillance in Central Kenya. AIDS Res Hum Retroviruses. 2011. [Epub ahead of print].
134. Nyagaka B, Kiptoo M, Lihana R, et al. HIV-1 gag genetic diversity among antenatal clinic attendees in North-Rift Valley, Kenya." AIDS Res Hum Retroviruses. 2011. [Epub ahead of print].
135. Oyaro M, Mbithi J, Oyugi F, Laten A, Anzala O, Engelbrecht S. Molecular characterization of HIV type 1 among HIV-infected respondents in a cohort being prepared for HIV Phase III vaccine clinical trials, Western Kenya." AIDS Res Hum Retroviruses. 2011;27:257-64.
136. Visawapoka U, Tovanabutra S, Currier J, et al. Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2. AIDS Res Hum Retroviruses. 2006;22:695-702.
137. Khamadi S, Lihana R, Mwaniki D, et al. HIV type 1 genetic diversity in Moyale, Mandera, and Turkana based on env-C2-V3 sequences. AIDS Res Hum Retroviruses. 2008;24:1561-4.
138. Servais J, Lambert C, Karita E, et al. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res Hum Retroviruses. 2004;20:279-83.
139. Galluzzo C, Germinario E, Bassani L, et al. Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda. AIDS Res Hum Retroviruses. 2007;23:1449-51.
140. Razafindratsimandresy R, Hollanda J, Soares J, Rousset D, Chetty A, Reynes J. HIV type 1 diversity in the Seychelles. AIDS Res Hum Retroviruses. 2007;23:761-3.
141. Razafindratsimandresy R, Rajaonatahina D, Soares J, Rousset D, Reynes J. High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar. AIDS Res Hum Retroviruses. 2006;22:595-7.
142. Hoelscher M, Hanker S, Barin F, et al. HIV type 1 V3 serotyping of Tanzanian samples: probable reasons for mismatching with genetic subtyping. AIDS Res Hum Retroviruses. 1998;14:139-49.
143. Arroyo M, Hoelscher M, Sanders-Buell E, et al. HIV type 1 subtypes among blood donors in the Mbeya region of southwest Tanzania. AIDS Res Hum Retroviruses. 2004;20:895-901.
144. Somi G, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther. 2008;13(Suppl 2):77-82.
145. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol. 2010;48:3158-64.
146. Mosha F, Urassa W, Aboud S, et al. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses. 2011;27:377-82.
147. Nofemela A, Bandawe G, Thebus R, et al. Defining the human immunodeficiency virus type 1 transmission genetic bottleneck in a region with multiple circulating subtypes and recombinant forms. Virology. 2011;415:107-13.
148. Koulinska I, Ndung'u T, Mwakagile D, et al. A new human immunodeficiency virus type 1 circulating recombinant form from Tanzania. AIDS Res Hum Retroviruses. 2001;17:423-31.
149. Hoelscher M, Dowling W, Sanders-Buell E, et al. Detection of HIV-1 subtypes, recombinants, and dual infections in east Africa by a multi-region hybridization assay. AIDS. 2002;16:2055-64.
150. Koulinska I, Msamanga G, Mwakagile D, Essex M, Renjifo B. Common genetic arrangements among human immunodeficiency virus type 1 subtype A and D recombinant genomes vertically transmitted in Tanzania. AIDS Res Hum Retroviruses. 2002;18:947-56.
151. Arroyo M, Hoelscher M, Sateren W, et al. HIV-1 diversity and prevalence differ between urban and rural areas in the Mbeya region of Tanzania. AIDS. 2005;19:1517-24.
152. Koulinska I, Chaplin B, Mwakagile D, Essex M, Renjifo B. Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses. 2003;19:1115-23.
153. Hu D, Baggs J, Downing R, et al. Predominance of HIV-1 subtype A and D infections in Uganda. Emerg Infect Dis. 2000;6:609-15.
154. Yirrell D, Kaleebu P, Morgan D, Hutchinson S, Whitworth J. HIV-1 subtype dynamics over 10 years in a rural Ugandan cohort. I J STD AIDS. 2004;15:103-6.
155. Gale C, Yirrell D, Campbell E, Van der Paal L, Grosskurth H, Kaleebu P. Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naive population in rural southwestern Uganda. AIDS Res Hum Retroviruses. 2006;22:985-92.
156. Herbeck J, Lyagoba F, Moore S, et al. Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Hum Retroviruses. 2007;23:755-60.
157. Hamers R, Wallis C, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750-9.
158. Ssemwanga D, Lyagoba F, Ndembi N, et al. Multiple HIV-1 infections with evidence of recombination in heterosexual partnerships in a low risk Rural Clinical Cohort in Uganda. Virology. 2011;411:113-31.
159. Ssemwanga D, Ndembi N, Lyagoba F, et al. HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses. 2011. [Epub ahead of print].
160. Okware S, Opio A, Musinguzi J, Waibale P. Fighting HIV/AIDS: is success possible? Bull World Health Organ. 2001;79:1113-20.
161. Dalai S, de Oliveira T, Harkins G, et al. Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS. 2009;23:2523-32.
162. Heyndrickx L, Janssens W, Zekeng L, et al. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study Group on Heterogeneity of HIV Epidemics in African Cities. J Virol. 2000;74:363-70.
163. Morison L, Buve A, Zekeng L, et al. HIV-1 subtypes and the HIV epidemics in four cities in sub-Saharan Africa. AIDS. 2001;15(Suppl 4):S109-16.
164. Monleau M, Affolabi D, Afangnihoun A, et al. Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin. J AIDS HIV Res. 2011;3:114-20.
165. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11:575-9.
166. Nadembega W, Giannella S, Simpore J, et al. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. J Med Virol. 2006;78:1385-91.
167. Simpore J, Pietra V, Pignatelli S, et al. Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso. J Med Virol. 2007;79:873-9.
168. Sylla M, Chamberland A, Boileau C, et al. Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02-AG and AGK subtypes in Mali and Burkina Faso. Antivir Ther. 2008;13:141-8.
169. Tebit D, Sangare L, Makamtse A, et al. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. J Acquir Immune Defic Syndr. 2008;49:17-25.
170. Tebit DM, Sangaré L, Tiba F, et al. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso J Med Virol. 2009;81(10):1691-701.
171. Ayouba A, Lien T, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study." AIDS Res Hum Retroviruses. 2009;25:1193-6.
172. Koch N, Ndihokubwayo J, Yahi N, Tourres C, Fantini J, Tamalet C. Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant. AIDS Res Hum Retroviruses. 2001;17:269-73.
173. Yamaguchi J, Vallari A, Swanson P, et al. Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters. AIDS Res Hum Retroviruses. 2002;18:269-82.
174. Yamaguchi J, Bodelle P, Vallari S, et al. HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Res Hum Retroviruses. 2004;20:944-57.
175. Vessiere A, Rousset D, Kfutwah A, et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr. 2010;53:107-10.
176. Zhong P, Burda S, Konings F, et al. Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity. AIDS Res Hum Retroviruses. 2003;19:1167-78.
177. Burda S, Konings F, Williams C, Anyangwe C, Nyambi P. HIV-1 CRF09-cpx circulates in the North West Province of Cameroon where CRF02-AG infections predominate and recombinant strains are common. AIDS Res Hum Retroviruses. 2004;20:1358-63.
178. Konings F, Haman G, Xue Y, et al. Genetic analysis of HIV-1 strains in rural eastern Cameroon indicates the evolution of second-generation recombinants to circulating recombinant forms. J Acquir Immune Defic Syndr. 2006;42:331-41.
179. Ndongmo C, Pieniazek D, Holberg-Petersen M, et al. HIV genetic diversity in Cameroon: possible public health importance. AIDS Res Hum Retroviruses. 2006;22:812-16.
180. Luk K, Holzmayer V, Yamaguchi J, et al. Near full-length genome characterization of three additional HIV type 1 CRF13-cpx strains from Cameroon. AIDS Res Hum Retroviruses. 2007;23:297-302.
181. Machuca A, Tang S, Hu J, et al. Increased genetic diversity and intersubtype recombinants of HIV-1 in blood donors from urban Cameroon. J Acquir Immune Defic Syndr. 2007;45:361-3.
182. Powell R, Zhao J, Konings F, et al. Circulating recombinant form (CRF) 37-cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G. AIDS Res Hum Retroviruses. 2007;23:923-33.
183. Ndembi N, Abraha A, Pilch H, et al. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol. 2008;46:177-84.
184. Brennan C, Bodelle P, Coffey R, et al. The prevalence of diverse HIV-1 strains was stable in Cameroonian blood donors from 1996 to 2004. J Acquir Immune Defic Syndr. 2008;49:432-9.
185. Takehisa J, Zekeng L, Ido E, et al. Various types of HIV mixed infections in Cameroon. Virology. 1998;245:1-10.
186. Peeters M, Liegeois F, Torimiro N, et al. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient." J Virol. 1999;73:7368-75.
187. Takehisa J, Zekeng L, Ido E, et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in cameroon. J Virol. 1999;73:6810-20.
188. Powell R, Urbanski M, Burda S, Kinge T, Nyambi P. High frequency of HIV-1 dual infections among HIV-positive individuals in Cameroon, West Central Africa. J Acquir Immune Defic Syndr. 2009;50:84-92.
189. Chan P, Wakeman S, Flanigan T, Cu-Uvin S, Kojic E, Kantor R. HIV-2 diagnosis and quantification in high-risk patients. AIDS Res Ther. 2008;5:18.
190. Punzi G, Saracino A, Brindicci G, et al. HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic. J Med Virol. 2005;77:457-9.
191. Marechal V, Jauvin V, Selekon B, et al. Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. AIDS Res Hum Retroviruses. 2006;22:1036-44.
192. Anderson J, Rodrigo A, Learn G, et al. Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E. J Virol. 2000;74:10752-65.
193. Lasky M, Perret J, Peeters M, et al. Presence of multiple non-B subtypes and divergent subtype B strains of HIV-1 in individuals infected after overseas deployment. AIDS. 1997;11:43-51.
194. Vidal N, Koyalta D, Richard V, et al. High genetic diversity of HIV-1 strains in Chad, West Central Africa. J Acquir Immune Defic Syndr. 2003;33:239-46.
195. Toni T, Masquelier B, Bonard D, et al. Primary HIV-1 drug resistance in Abidjan (Cote d'Ivoire): a genotypic and phenotypic study. AIDS. 2002;16:488-91.
196. Adje-Toure C, Bile C, Borget M, et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02-AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2003;34:111-13.
197. Adje-Toure C, Celestin B, Hanson D, et al. Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Cote d'Ivoire. AIDS. 2003;17(Suppl 3):S23-9.
198. Sawadogo S, Adje-Toure C, Bilé C, Ekpini R, Chorba T, Nkengasong J. Field evaluation of the gag-based heteroduplex mobility assay for genetic subtyping of circulating recombinant forms of human immunodeficiency virus type 1 in Abidjan, Cote d'Ivoire. J Clin Microbiol. 2003;41:3056-9.
199. Toni T, Recordon-Pinson P, Minga A, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Cote d'Ivoire: ANRS 1257 study." AIDS Res Hum Retroviruses. 2003;19:713-17.
200. Bile E, Adje-Toure C, Borget M, et al. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02-AG strains of HIV-1 in Abidjan, Cote d'Ivoire. J Clin Virol. 2005;32:60-6.
201. Chaix M, Rouet F, Kouakoussui K, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-6.
202. Toni T, Masquelier B, Minga A, et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cote d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses. 2007;23:1155-60.
203. Kalish M, Robbins K, Pieniazek D, et al. Recombinant viruses and early global HIV-1 epidemic. Emerg Infect Dis. 2004;10:1227-34.
204. Vidal N, Mulanga C, Bazepeo S, et al. Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J Acquir Immune Defic Syndr. 2005;40:456-62.
205. Yang C, Li M, Mokili J, et al. Genetic diversification and recombination of HIV type 1 group M in Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses. 2005;21:661-6.
206. Vidal N, Mulanga C, Bazepeo S, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202-6.
207. Vidal N, Bazepeo S, Mulanga C, et al. Genetic characterization of eight full-length HIV type 1 genomes from the Democratic Republic of Congo (DRC) reveal a new subsubtype, A5, in the A radiation that predominates in the recombinant structure of CRF26-A5U. AIDS Res Hum Retroviruses. 2009;25:823-32.
208. Djoko C, Rimoin A, Vidal N, et al. High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, Democratic Republic of the Congo. AIDS Res Hum Retroviruses. 2011;27:323-9.
209. Muwonga J, Edidi S, Butel C, et al. Resistance to Antiretroviral Drugs in Treated and Drug-Naive Patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2011;57:27-33.
210. Kita K, Ndembi N, Ekwalanga M, et al. Genetic diversity of HIV type 1 in Likasi, southeast of the Democratic Republic of Congo. AIDS Res Hum Retroviruses. 2004;20:1352-7.
211. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol. 2000;74:10498-507.
212. Yang C, Dash B, Hanna S, et al. Predominance of HIV type 1 subtype G among commercial sex workers from Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses. 2001;17:361-5.
213. Ortiz M, Sanchez I, Gonzalez M, et al. Molecular epidemiology of HIV type 1 subtypes in equatorial guinea. AIDS Res Hum Retroviruses. 2001;17:851-5.
214. Meloni S, Kim B, Sankalé J, et al. Distinct human immunodeficiency virus type 1 subtype A virus circulating in West Africa: sub-subtype A3. J Virol. 2004;78:12438-45.
215. Djoko C, Wolfe N, Vidal N, et al. HIV type 1 pol gene diversity and genotypic antiretroviral drug resistance mutations in Malabo, Equatorial Guinea. AIDS Res Hum Retroviruses. 2010;26:1027-31.
216. Caron M, Makuwa M, Souquière S, Descamps D, Brun-Vézinet F, Kazanji M. Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa. AIDS Res Hum Retroviruses. 2008;24:1225-8.
217. Mintsa-Ndong A, Caron M, Plantier J, et al. High HIV Type 1 prevalence and wide genetic diversity with dominance of recombinant strains but low level of antiretroviral drug-resistance mutations in untreated patients in northeast Gabon, Central Africa. AIDS Res Hum Retroviruses. 2009;25:411-18.
218. Makuwa M, Souquiere S, Apetrei C, Tevi-Benissan C, Bedjabaga I, Simon F. HIV prevalence and strain diversity in Gabon: the end of a paradox. AIDS. 2000;14:1275-6.
219. van der Loeff M, Awasana A, Sarge-Njie R, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol. 2006;35:1322-8.
220. de Silva T, Turner R, Hué, S, et al. HIV-1 subtype distribution in the Gambia and the significant presence of CRF49-cpx, a novel circulating recombinant form. Retrovirology. 2010;7:82.
221. Jallow S, Alabi A, Sarge-Njie R, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009;47:2200-8.
222. Sagoe K, Dwidar M, Lartey M, et al. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J Clin Virol. 2007;40:163-7.
223. Delgado E, Ampofo W, Sierra M, et al. High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study. J Acquir Immune Defic Syndr. 2008;48:599-606.
224. Chaillet P, Tayler-Smith K, Zachariah R, et al. Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea- Conakry, West Africa. Trans R Soc Trop Med Hyg. 2010; 104:571-6.
225. Mansson F, Camara C, Biai A, et al. High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa. Int J STD AIDS. 2010;21:631-5.
226. Mansson F, Biague A, da Silva Z, et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS. 2009;23:1575-82.
227. Derache A, Traore O, Koita V, et al. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther. 2007;12:123-9.
228. Derache A, Maiga A, Traore O, et al. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother. 2008;62:456-63.
229. Imamichi H, Koita O, Dabitao D, et al. Identification and characterization of CRF02-AG, CRF06-cpx, and CRF09-cpx recombinant subtypes in Mali, West Africa. AIDS Res Hum Retroviruses. 2009;25:45-55.
230. Haidara A, Chamberland A, Sylla M, et al. High level of primary drug resistance in Mali. HIV Med. 2010;11:404-11.
231. Mamadou S, Montavon C, Ben A, et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res Hum Retroviruses. 2002;18:723-6.
232. Mamadou S, Vidal N, Montavon C, et al. Emergence of complex and diverse CRF02-AG/CRF06-cpx recombinant HIV type 1 strains in Niger, West Africa. AIDS Res Hum Retroviruses. 2003;19:77-82.
233. Peeters M, Vergne E, Montavon L, et al. Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses. 2000;16:315-25.
234. Vicente A, Agwale S, Otsuki K, et al. Genetic variability of HIV-1 protease from Nigeria and correlation with protease inhibitors drug resistance. Virus Genes. 2001;22:181-6.
235. Ojesina A, Sankale J, Odaibo G, et al. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses. 2006;22:770-9.
236. Ojesina A, Mullins C, Imade G, et al. Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria. AIDS Res Hum Retroviruses. 2007;23:1587-92.
237. Ojesina A, Chaplin B, Sankalé J, et al. Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02-AG. AIDS Res Hum Retroviruses. 2008;24:1167-74.
238. Hawkins C, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr. 2009;52:228-34.
239. Ajoge H, Gordon M, de Oliveira T, et al. Genetic characteristics, coreceptor usage potential and evolution of Nigerian HIV-1 subtype G and CRF02-AG isolates. PLoS One. 2011;6:e17865.
240. Ajoge H, Gordon M, et al. Drug Resistance Pattern of HIV Type 1 Isolates Sampled in 2007 from Therapy-Naive Pregnant Women in North-Central Nigeria. AIDS Res Hum Retroviruses. 2012;28:115-8.
241. Chaplin B, Idoko G, Onwujekwe J, et al. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses. 2011;27:71-80.
242. Niama F, Toure-Kane C, Vidal N, et al. HIV-1 subtypes and recombinants in the Republic of Congo. Infect Genet Evol. 2006;6:337-43.
243. Bikandou B, Takehisa J, Mboudjeka I, et al. Genetic subtypes of HIV type 1 in Republic of Congo. AIDS Res Hum Retroviruses. 2000;16:613-19.
244. Taniguchi Y, Takehisa J, Bikandou B, et al. Genetic subtypes of HIV type 1 based on the vpu/env sequences in the Republic of Congo. AIDS Res Hum Retroviruses. 2002;18:79-83.
245. Bikandou B, Ndoundou-Nkodia M, Niama F, et al. Genetic subtyping of gag and env regions of HIV type 1 isolates in Republic of Congo. AIDS Res Hum Retroviruses. 2004;20:1005-9.
246. Laurent C, Diakhate N, Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-70.
247. Vergne L, Kane C, Laurent C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS. 2003;17(Suppl 3):S31-8.
248. Hamel D, Sankale J, Eisen G, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses. 2007;23:1189-96.
249. Diop-Ndiaye H, Toure-Kane C, Leye N, et al. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res Hum Retroviruses. 2010;26:1133-8.
250. MacNeil A, Sankale J, Meloni S, Sarr A, Mboup S, Kanki P. Long-term intrapatient viral evolution during HIV-2 infection. J Infect Dis. 2007;195:726-33.
251. Toure-Kane C, Montavon C, Faye M, et al. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res Hum Retroviruses. 2000;16:603-9.
252. Meloni S, Sankale J, Hamel D, et al. Molecular epidemiology of human immunodeficiency virus type 1 sub-subtype A3 in Senegal from 1988 to 2001. J Virol. 2004;78:12455-61.
253. Ndiaye H, Toure-Kane C, Vidal N, et al. Surprisingly high prevalence of subtype C and specific HIV-1 subtype/CRF distribution in men having sex with men in Senegal. J Acquir Immune Defic Syndr. 2009;52:249-52.
254. Hamers R, Wensing A, Back N, Arcilla M, Frissen J. Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine. Antivir Ther. 2011;16:115-18.
255. Smith S, Christian D, de Lame V, et al. Isolation of a new HIV-2 group in the US. Retrovirology. 2008;5:103.
256. Yaotse D, Nicole V, Roch N, Mireille P, Eric D, Martine P. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. Infect Genet Evol. 2009;9:646-52.
257. Elharti E, Alami M, Khattabi H, et al. Some characteristics of the HIV epidemic in Morocco. East Mediterr Health J. 2002;8:819-25.
258. Mumtaz G, Hilmi N, Akala F, et al. HIV-1 molecular epidemiology evidence and transmission patterns in the Middle East and North Africa. Sex Transm Infect. 2011;87:101-6.
259. Mumtaz G, Hilmi N, McFarland W, et al. Are HIV Epidemics among Men Who Have Sex with Men Emerging in the Middle East and North Africa?: A Systematic Review and Data Synthesis. PLoS Med. 2010;8(8):e1000444.
260. Bouzeghoub S, Jauvin V, Recordon-Pinson P, et al. High diversity of HIV type 1 in Algeria. AIDS Res Hum Retroviruses. 2006;22:367-72.
261. Bouzeghoub S, Jauvin V, Pinson P, et al. First observation of HIV type 1 drug resistance mutations in Algeria. AIDS Res Hum Retroviruses. 2008;24:1467-73.
262. Carr J, Salminen M, Albert J, et al. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology. 1998;247:22-31.
263. El Sayed N, Gomatos P, Beck-Sagué C, et al. Epidemic transmission of human immunodeficiency virus in renal dialysis centers in Egypt. J Infect Dis. 2000;181:91-7.
264. Visco-Comandini U, Longo B, Perinelli P, et al. Possible child-to-mother transmission of HIV by breastfeeding. JAMA. 2005;294:2301-2.
265. de Oliveira T, Pybus O, Rambaut A, et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature. 2006;444:836-7.
266. Elharti E, Elaouad R, Amzazi S, et al. HIV-1 diversity in Morocco. AIDS. 1997;11:1781-3.
267. Abid M, Luo C, Sekkat S, et al. Characterization of the V3 region of HIV type 1 isolates from Morocco. AIDS Res Hum Retroviruses. 1998;14:1387-9.
268. Bakhouch K, Oulad-Lahcen A, Bensghir R, et al. The prevalence of resistance- associated mutations to protease and reverse transcriptase inhibitors in treatment-naive (HIV1)-infected individuals in Casablanca, Morocco. J Infect Dev Ctries. 2009;3:380-91.
269. Annaz H, Recordon-Pinson P, Baba N, Sedrati O, Mrani S, Fleury H. Presence of drug resistance mutations among drug-naive patients in Morocco. AIDS Res Hum Retroviruses. 2011;27:917-20.
270. Khamadi S, Ochieng W, Lihana R, et al. HIV type 1 subtypes in circulation in northern Kenya. AIDS Res Hum Retroviruses. 2005;21:810-14.
271. Ben Halima M, Pasquier C, Slim A, et al. First molecular characterization of HIV-1 Tunisian strains. J Acquir Immune Defic Syndr. 2001;28:94-6.
272. Karray-Hakim H, Barin F, Fki-Berrajah L, Kanoun F, Ben Jmaa M, Hammami A. [Characterization of HIV-1 subtypes in Sfax, Tunisia]. Tunis Med. 2003;81:184-9.
273. Vidal N, Niyongabo T, Nduwimana J, et al. HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. AIDS Res Hum Retroviruses. 2007;23:175-80.